CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Invivyd Inc. - IVVD CFD

    1.57
    0.63%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Invivyd Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.58
    Open* 1.61
    1-Year Change* -44.86%
    Day's Range* 1.57 - 1.61
    52 wk Range 0.98-4.89
    Average Volume (10 days) 209.70K
    Average Volume (3 months) 8.00M
    Market Cap 194.27M
    P/E Ratio -100.00K
    Shares Outstanding 109.76M
    Revenue N/A
    EPS -1.61
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 25, 2023 1.58 -0.03 -1.86% 1.61 1.62 1.55
    Sep 22, 2023 1.61 0.01 0.63% 1.60 1.62 1.55
    Sep 21, 2023 1.64 -0.09 -5.20% 1.73 1.75 1.62
    Sep 20, 2023 1.74 -0.05 -2.79% 1.79 1.82 1.73
    Sep 19, 2023 1.82 0.01 0.55% 1.81 1.86 1.76
    Sep 18, 2023 1.84 0.07 3.95% 1.77 1.85 1.77
    Sep 15, 2023 1.74 0.02 1.16% 1.72 1.83 1.72
    Sep 14, 2023 1.73 -0.05 -2.81% 1.78 1.80 1.72
    Sep 13, 2023 1.75 -0.11 -5.91% 1.86 1.95 1.75
    Sep 12, 2023 1.88 0.06 3.30% 1.82 1.91 1.82
    Sep 11, 2023 1.81 0.09 5.23% 1.72 1.90 1.68
    Sep 8, 2023 1.76 0.01 0.57% 1.75 1.79 1.66
    Sep 7, 2023 1.76 0.06 3.53% 1.70 1.77 1.69
    Sep 6, 2023 1.73 0.01 0.58% 1.72 1.77 1.70
    Sep 5, 2023 1.80 0.01 0.56% 1.79 1.83 1.69
    Sep 1, 2023 1.82 0.00 0.00% 1.82 1.86 1.79
    Aug 31, 2023 1.85 0.02 1.09% 1.83 1.87 1.83
    Aug 30, 2023 1.83 -0.03 -1.61% 1.86 1.87 1.79
    Aug 29, 2023 1.84 0.09 5.14% 1.75 1.87 1.75
    Aug 28, 2023 1.79 0.03 1.70% 1.76 1.86 1.75

    Invivyd Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020
    Total revenue 0 0 0
    Total Operating Expense 230.658 226.908 65.327
    Selling/General/Admin. Expenses, Total 47.044 36.517 3.21
    Research & Development 183.614 190.391 62.117
    Operating Income -230.658 -226.908 -65.327
    Interest Income (Expense), Net Non-Operating 3.9 1.7 0.008
    Net Income Before Taxes -241.317 -226.79 -65.319
    Net Income After Taxes -241.317 -226.79 -65.319
    Net Income Before Extra. Items -241.317 -226.79 -65.319
    Net Income -241.317 -226.79 -65.319
    Income Available to Common Excl. Extra. Items -241.317 -226.79 -65.319
    Income Available to Common Incl. Extra. Items -241.317 -226.79 -65.319
    Diluted Net Income -241.317 -226.79 -65.319
    Diluted Weighted Average Shares 108.268 42.6213 108.516
    Diluted EPS Excluding Extraordinary Items -2.22888 -5.32105 -0.60193
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -2.22888 -5.32105 -0.60193
    Other, Net -14.559 -1.582
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 53.875 39.071 30.839 47.331 51.749
    Selling/General/Admin. Expenses, Total 10.107 11.045 10.52 13.2 14.62
    Research & Development 43.768 28.026 20.319 34.131 37.129
    Operating Income -53.875 -39.071 -30.839 -47.331 -51.749
    Interest Income (Expense), Net Non-Operating 1.6 1.1 3.8 0.1
    Net Income Before Taxes -50.228 -35.321 -44.574 -45.087 -50.99
    Net Income After Taxes -50.228 -35.321 -44.574 -45.087 -50.99
    Net Income Before Extra. Items -50.228 -35.321 -44.574 -45.087 -50.99
    Net Income -50.228 -35.321 -44.574 -45.087 -50.99
    Income Available to Common Excl. Extra. Items -50.228 -35.321 -44.574 -45.087 -50.99
    Income Available to Common Incl. Extra. Items -50.228 -35.321 -44.574 -45.087 -50.99
    Diluted Net Income -50.228 -35.321 -44.574 -45.087 -50.99
    Diluted Weighted Average Shares 109.45 108.786 108.61 108.421 108.167
    Diluted EPS Excluding Extraordinary Items -0.45891 -0.32468 -0.4104 -0.41585 -0.4714
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.45891 -0.32468 -0.4104 -0.41585 -0.4714
    Other, Net 2.047 2.65 -17.535 2.244 0.659
    • Annual
    • Quarterly
    2022 2021 2020
    Total Current Assets 376.917 616.711 117.382
    Cash and Short Term Investments 371.991 591.418 114.988
    Cash & Equivalents 92.076 542.224 114.988
    Prepaid Expenses 4.549 25.293 2.253
    Other Current Assets, Total 0.141
    Total Assets 383.167 620.091 117.382
    Total Current Liabilities 25.031 62.06 13.072
    Accounts Payable 1.517 5.783 8.153
    Accrued Expenses 23.47 56.277 4.919
    Notes Payable/Short Term Debt 0 0 0
    Total Liabilities 27.197 62.072 13.083
    Total Long Term Debt 0 0 0
    Other Liabilities, Total 2.166 0.012 0.011
    Total Equity 355.97 558.019 104.299
    Preferred Stock - Non Redeemable, Net 0 0 169.548
    Common Stock 0.011 0.011 0
    Additional Paid-In Capital 889.657 850.125 0.155
    Retained Earnings (Accumulated Deficit) -533.426 -292.109 -65.319
    Treasury Stock - Common -0.085
    Total Liabilities & Shareholders’ Equity 383.167 620.091 117.382
    Total Common Shares Outstanding 109.044 110.783 108.516
    Short Term Investments 279.915 49.194
    Property/Plant/Equipment, Total - Net 6.059 0.083
    Other Long Term Assets, Total 0.191 3.297
    Other Equity, Total -0.272 -0.008
    Total Receivables, Net 0.377
    Other Current Liabilities, Total 0.044
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 344.623 376.917 421.596 481.361 554.301
    Cash and Short Term Investments 333.428 371.991 418.669 474.885 532.22
    Cash & Equivalents 126.473 92.076 278.152 474.885 532.22
    Prepaid Expenses 10.662 4.549 2.142 6.476 22.081
    Other Current Assets, Total
    Total Assets 350.564 383.167 424.747 484.612 556.273
    Total Current Liabilities 22.057 25.031 46.126 67.883 95.534
    Accounts Payable 5.913 1.517 16.77 14.232 18.682
    Accrued Expenses 16.086 23.47 29.303 53.593 76.852
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 23.815 27.197 47.304 69.773 96.881
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 1.758 2.166 1.178 1.89 1.347
    Total Equity 326.749 355.97 377.443 414.839 459.392
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.011 0.011 0.011 0.011 0.011
    Additional Paid-In Capital 895.6 889.657 866.238 858.593 852.156
    Retained Earnings (Accumulated Deficit) -568.747 -533.426 -488.852 -443.765 -392.775
    Treasury Stock - Common 0 0 0
    Total Liabilities & Shareholders’ Equity 350.564 383.167 424.747 484.612 556.273
    Total Common Shares Outstanding 109.316 109.044 108.957 108.781 109.675
    Other Long Term Assets, Total 0.291 0.191 0.236 0.299 0.237
    Short Term Investments 206.955 279.915 140.517 0 0
    Total Receivables, Net 0.533 0.377 0.785
    Other Equity, Total -0.115 -0.272 0.046 0 0
    Property/Plant/Equipment, Total - Net 5.65 6.059 2.915 2.952 1.735
    Other Current Liabilities, Total 0.058 0.044 0.053 0.058
    • Annual
    • Quarterly
    2022 2021 2020
    Net income/Starting Line -241.317 -226.79 -65.319
    Cash From Operating Activities -219.987 -184.736 -14.571
    Non-Cash Items 37.419 19.26 40.07
    Changes in Working Capital -16.13 22.793 10.678
    Cash From Financing Activities 0.506 662.683 129.559
    Issuance (Retirement) of Stock, Net 0.506 666.068 129.559
    Net Change in Cash -450.148 427.236 114.988
    Cash From Operating Activities 0.041 0.001
    Cash From Investing Activities -230.667 -50.711
    Capital Expenditures -1.705 -0.084
    Other Investing Cash Flow Items, Total -228.962 -50.627
    Financing Cash Flow Items 0 -3.385
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -35.321 -241.317 -196.743 -151.656 -100.666
    Cash From Operating Activities -41.181 -219.987 -172.583 -116.441 -59.049
    Non-Cash Items 3.236 37.419 16.077 8.749 2.257
    Changes in Working Capital -9.216 -16.13 8.069 26.457 39.356
    Cash From Financing Activities 0.542 0.506 0.365 0.119 0.045
    Issuance (Retirement) of Stock, Net 0.542 0.506 0.365 0.119 0.045
    Net Change in Cash 34.397 -450.148 -264.072 -67.339 -10.004
    Financing Cash Flow Items 0 0 0
    Cash From Investing Activities 75.036 -230.667 -91.854 48.983 49
    Other Investing Cash Flow Items, Total 75.66 -228.962 -91.36 49 49
    Cash From Operating Activities 0.12 0.041 0.014 0.009 0.004
    Capital Expenditures -0.624 -1.705 -0.494 -0.017
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Adimab, L.L.C. Corporation 24.3158 26687906 0 2022-06-22
    Mithril Capital Management LLC Venture Capital 10.2424 11241580 0 2022-07-05 LOW
    Fidelity Management & Research Company LLC Investment Advisor 9.0559 9939351 -4009584 2023-06-30 LOW
    M28 Capital Management LP Investment Advisor 8.4262 9248250 0 2023-06-30 MED
    Polaris Venture Partners Venture Capital 7.7734 8531700 0 2022-06-22 LOW
    Alphabet, Inc. Venture Capital 5.1758 5680785 0 2023-06-30 LOW
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 4.8019 5270400 0 2023-06-30 LOW
    683 Capital Management LLC Hedge Fund 3.6445 4000000 600000 2023-06-30 MED
    Slate Path Capital LP Investment Advisor 3.403 3735000 0 2023-06-30 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.2678 2489014 -210968 2023-06-30 LOW
    Maverick Capital, Ltd. Hedge Fund 2.1305 2338373 450846 2023-06-30 MED
    Citi Investment Research (US) Research Firm 2.1203 2327146 2325904 2023-06-30 MED
    Bain Capital Life Sciences Investors, LLC Investment Advisor 1.765 1937207 0 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 1.7638 1935875 409716 2023-06-30 HIGH
    Redmile Group, LLC Investment Advisor/Hedge Fund 1.3127 1440725 0 2023-06-30 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 1.1351 1245823 -2192562 2023-06-30 LOW
    Population Health Partners, L.P. Corporation 1.0949 1201680 0 2022-06-22
    Tang Capital Management, LLC Hedge Fund 1.0495 1151843 751843 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.4716 517594 -519603 2023-06-30 LOW
    Bridgeway Capital Management, LLC Investment Advisor 0.2716 298100 -10000 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Invivyd Inc. Company profile

    About Adagio Therapeutics Inc

    Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Adagio Therapeutics Inc revenues was not reported. Net loss increased from $48.1M to $143.7M. Higher net loss reflects Research and development increase from $7.3M to $110.9M (expense), Selling, general and administrative increase from $890K to $15.5M (expense), Stock-based Compensation in SGA increase from $2K to $6.3M (expense).

    Industry: Bio Therapeutic Drugs

    1601 Trapelo Road
    Suite 178
    WALTHAM
    MASSACHUSETTS 02451
    US

    Income Statement

    • Annual
    • Quarterly

    News

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023

    People also watch

    BTC/USD

    26,200.40 Price
    -0.510% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.51 Price
    +0.090% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    US100

    14,587.40 Price
    -1.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    ETH/USD

    1,587.99 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading